Skin cancer

DermBiont Announces 2024 Development Pipeline Update for its First-in-Class Targeted Topical Therapeutics for Seborrheic Keratoses, Basal Cell Carcinomas, and Melasma

Retrieved on: 
Thursday, February 22, 2024

DermBiont currently anticipates that data will be available in Q3 2024.

Key Points: 
  • DermBiont currently anticipates that data will be available in Q3 2024.
  • SKs: DermBiont expects to report data from its CT-213 Phase 2b clinical trial of SM-020 gel 1.0% in Q3 2024.
  • BCCs and SCCISs: DermBiont expects to initiate its CT-217 Phase 2a clinical trial in Q1 2024 and report data in Q3 2024.
  • Melasma: DermBiont anticipates enrolling the first patient in its randomized, observer-blinded, vehicle-controlled CT-214 Phase 2b trial of SM-030 in 138 subjects with melasma in Q2 2024.

SkinCure Oncology Unveils New Skin Cancer Treatment Technology at American Academy of Dermatology Annual Meeting in San Diego March 8-12 Booth 3555

Retrieved on: 
Thursday, March 7, 2024

Reflective confocal microscopy, or RCM, will provide high resolution imaging of the epidermis, to a depth of 200 microns, for cellular level visualization of skin cancer lesions.

Key Points: 
  • Reflective confocal microscopy, or RCM, will provide high resolution imaging of the epidermis, to a depth of 200 microns, for cellular level visualization of skin cancer lesions.
  • Brandt noted, "Mohs micrographic surgery has been the gold standard of care for the treatment of nonmelanoma skin cancer (NMSC) for more than 50 years.
  • "SkinCure Oncology," Brandt continued, "is helping dermatologists nationwide implement the GentleCure Experience – an advanced, noninvasive treatment for NMSC.
  • The new devices will feature technology for which SkinCure Oncology was recently awarded U.S. patent coverage.

SAVE YOUR SKIN FOUNDATION & OPHA LAUNCH 2ND ANNUAL HAIR HEROES CHALLENGE

Retrieved on: 
Tuesday, February 27, 2024

The Hair Heroes Challenge is a social media campaign that aims to spread awareness about Sty-Lives, an initiative that teaches hairstylists and students how to check their client's scalps for skin cancer.

Key Points: 
  • The Hair Heroes Challenge is a social media campaign that aims to spread awareness about Sty-Lives, an initiative that teaches hairstylists and students how to check their client's scalps for skin cancer.
  • TORONTO, Feb. 27, 2024 /CNW/ - From February 16th to April 19th, Save Your Skin Foundation and OPHA will run the 2nd annual Hair Heroes Challenge, a social media campaign that encourages hairstylists and students to practice checking for potential skin cancer spots on their clients while giving them opportunity to win prizes!
  • Sty-Lives (Styling Hair & Saving Lives) is an initiative of Save Your Skin Foundation.
  • To learn more about the Hair Heroes Challenge, Sty-Lives and how to participate, click here !

Dallas Dermatology Partners Named Among D Magazine's 2023 Best Doctors

Retrieved on: 
Wednesday, February 21, 2024

DALLAS, Feb. 21, 2024 /PRNewswire/ -- Dallas Dermatology Partners proudly recognizes all five partners for being peer-selected among D Magazine's best dermatologists in Dallas for 2023.

Key Points: 
  • DALLAS, Feb. 21, 2024 /PRNewswire/ -- Dallas Dermatology Partners proudly recognizes all five partners for being peer-selected among D Magazine's best dermatologists in Dallas for 2023.
  • The final list is selected by their peers, who are other practicing physicians in Dallas, and represents the most "esteemed, exceptionally skilled, and compassionate" Dallas doctors.
  • Meet the Dallas Dermatology Partners included on this year's roster.
  • Dr. Melissa Costner holds the distinction among Dallas Dermatology Partners as the doctor with the longest record— 19 years — of being named among the area's "Best Doctors" list.

Medical Journal: Image-Guided Superficial Radiation Therapy Is Superior to Superficial Radiation Therapy Without Guidance

Retrieved on: 
Tuesday, February 20, 2024

BURR RIDGE, Ill., Feb. 20, 2024 /PRNewswire/ -- SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT) for the treatment of nonmelanoma skin cancer, presented to dermatology patients as the GentleCure™ experience, announced the publication of research, "Image guidance improves freedom from recurrence in superficial radiation therapy for non-melanoma skin cancer," in Advances in Radiation Oncology, a peer-reviewed journal from the American Society for Radiation Oncology (ASTRO).

Key Points: 
  • It shows definitively that the new technology is superior, and represents a seminal moment in the care of skin cancer patients using radiation.
  • This study is the first to rigorously compare SRT to IGSRT, and it covers all the data that exists on IGSRT.
  • Superficial radiation therapy was developed over 100 years ago ( here ) and was the standard therapy for nonmelanoma skin cancer until Mohs micrographic surgery emerged in the 1930's ( here ).
  • IGSRT and the GentleCure experience will be showcased at the upcoming American Academy of Dermatology annual meeting in San Diego, at booth 3555.

FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

Retrieved on: 
Friday, February 16, 2024

"Unresectable or metastatic melanoma is an aggressive form of cancer that can be fatal," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research (CBER).

Key Points: 
  • "Unresectable or metastatic melanoma is an aggressive form of cancer that can be fatal," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research (CBER).
  • Melanoma can spread to other parts of the body if not detected and treated early, resulting in metastatic disease.
  • Treatment for unresectable or metastatic melanoma may include immunotherapy using PD-1 inhibitors, which are antibodies targeting certain proteins in the body to help the immune system fight off cancer cells.
  • Those patients whose melanoma has progressed with these therapies have a high unmet medical need.

La Jolla Vein & Vascular Adds New Medical Specialty; Opens Dermatology Clinic in Vista

Retrieved on: 
Thursday, February 15, 2024

La Jolla Vein & Vascular adds new specialist to offer dermatology services in Vista.

Key Points: 
  • La Jolla Vein & Vascular adds new specialist to offer dermatology services in Vista.
  • The dermatology clinic is set to open in March, and is located at 906 Sycamore Ave, Suite 100, Vista, California.
  • View the full release here: https://www.businesswire.com/news/home/20240215088694/en/
    Dr. Heidi Busch, a board-certified dermatologist joins La Jolla Vein & Vascular to spearhead their expansion of services with a new Medical and Cosmetic Dermatology clinic in Vista, California.
  • To schedule a consultation with Dr. Busch, call 760-249-7007 or learn more about La Jolla Vein & Vascular’s services at www.ljvascular.com .

What are ‘collarium’ sunbeds? Here’s why you should stay away

Retrieved on: 
Wednesday, February 14, 2024

A collarium sunbed emits both UV radiation and a mix of visible wavelength colours to produce a pink or red light.

Key Points: 
  • A collarium sunbed emits both UV radiation and a mix of visible wavelength colours to produce a pink or red light.
  • Like an old-school sunbed, the user lies in it for ten to 20 minute sessions to quickly develop a tan.

Why were sunbeds banned?

  • Commercial sunbeds have been illegal across Australia since 2016 (except for in the Northern Territory) under state-based radiation safety laws.
  • Their dangers were highlighted by young Australians including Clare Oliver who developed melanoma after using sunbeds.
  • Research shows people who have used sunbeds at least once have a 41% increased risk of developing melanoma, while ten or more sunbed sessions led to a 100% increased risk.

How are collarium sunbeds supposed to be different?

  • Australian sellers of collarium sunbeds imply they are safe, but their machine descriptions note the use of UV radiation, particularly UVA.
  • UVA is one part of the spectrum of UV radiation.
  • Evidence shows all types of sunbeds increase the risk of melanoma, including those that use only UVA.

Collagen claims

  • One particularly odd claim about collarium sunbeds is that they stimulate collagen.
  • Collagen is the main supportive tissue in our skin.
  • The reactive oxygen species generated by UVA light damage existing collagen structures and kick off a molecular chain of events that downgrades collagen-producing enzymes and increases collagen-destroying enzymes.
  • Over time, a build-up of degraded collagen fragments in the skin promotes even more destruction.

What about phototherapy?

  • The anti-collagen effects of UVA can also be used to treat thickened scars and keloids.
  • Side-effects of UV phototherapy include tanning, itchiness, dryness, cold sore virus reactivation and, notably, premature skin ageing.

So what happens now?

  • It looks like many collariums are just sunbeds rebranded with red light.
  • Queensland Health is currently investigating whether these salons are breaching the state’s Radiation Safety Act, and operators could face large fines.


Katie Lee receives funding from the National Health and Medical Research Council. Anne Cust receives funding from the National Health and Medical Research Council and Medical Research Future Fund.

Olansky Dermatology & Aesthetics welcomes Dr. Ajdin Kobic to acclaimed roster

Retrieved on: 
Wednesday, February 14, 2024

ATLANTA, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Olansky Dermatology & Aesthetics –Georgia’s top-rated dermatology practice– welcomes Dr. Ajdin Kobic, a board-certified dermatologist and fellowship-trained Mohs micrographic and reconstructive surgeon.

Key Points: 
  • ATLANTA, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Olansky Dermatology & Aesthetics –Georgia’s top-rated dermatology practice– welcomes Dr. Ajdin Kobic, a board-certified dermatologist and fellowship-trained Mohs micrographic and reconstructive surgeon.
  • With the addition of Dr. Kobic to the practice’s acclaimed team, patients can continue to choose Olansky Dermatology & Aesthetics with confidence.
  • “Patients looking to rejuvenate and revitalize their appearance have an incredible asset in Dr. Kobic,” says Dr. Jodi Ganz, physician partner at Olansky Dermatology & Aesthetics.
  • To schedule an appointment with Dr. Kobic at Olansky Dermatology & Aesthetics, visit OlanskyDermatology.com/Schedule or call: 404-355-5484.

SkinCure Oncology Awarded Patent for Next-Generation Image-Guided Superficial Radiation Therapy

Retrieved on: 
Wednesday, February 14, 2024

BURR RIDGE, Ill., Feb. 14, 2024 /PRNewswire/ -- SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT) for the treatment of nonmelanoma skin cancer, presented to dermatology patients as the GentleCure™ experience, today announced receipt of a patent from the U.S. Patent and Trademark Office for a new image-guided technology that will be the fourth generation of SRT. Although not yet submitted to the U.S. Food and Drug Administration for marketing clearance, the new devices will aim to embody cutting-edge technology in line with SkinCure Oncology's vision for the future of dermatology. If cleared by the FDA, they will utilize hybrid laser-generated confocal and photoacoustic imaging in a single fused volumetric image, which the company expects will allow clinicians to better image nonmelanoma skin cancers and deliver more accurate treatment.

Key Points: 
  • SkinCure Oncology Chief Executive Officer Kerwin Brandt stated, "The new devices are being designed to treat nonmelanoma skin cancer faster and more accurately than ever before.
  • Additionally, SkinCure Oncology, as an industry leader, will be introducing other groundbreaking technologies, subject to FDA clearance, that the company believes could shape the future of the diagnosis and treatment of nonmelanoma skin cancer.
  • "Patient care is the number one priority at SkinCure Oncology," said CEO Brandt.
  • We continue to change the face of skin cancer treatment globally through both our comprehensive model and soon through our emerging new technology."